Back to BAYRYView full pipeline
Phase 2
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
3 competitors in Non-small Cell Lung Carcinoma
View Full LandscapeDrug Information
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA9/25/2013
Giotrif
Giotrif as monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s); locally advanced or metastatic NSCLC of squamous histology progressing on or after platinum-based chemotherapy.
View on EMADrug Science
Mechanism of action & safety profile
Developer
Related Pipeline
Cipro XR (Ciprofloxacin, BAYQ3939)Phase 3
Urinary Tract Infection
DabigatranPhase 3
Hematoma
bemdaneprocelPhase 3
Parkinsons Disease (PD)
D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IVPhase 3
Acute Coronary Syndrome
Finerenone (Kerendia, BAY94-8862)Phase 3
Chronic Kidney Disease
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts